Changes in anxiety symptoms of ADHD adult patients with co-morbid refractory generalized anxiety disorder treated with mixed amphetamine salts (ADDERALL XR): An open label study

Journal of Affective Disorders ◽

10.1016/j.jad.2010.02.070 ◽

2010 ◽

Vol 122 ◽

pp. S58

Author(s):

A. Gabriel

Keyword(s):

Anxiety Disorder ◽

Generalized Anxiety Disorder ◽

Anxiety Symptoms ◽

Adult Patients ◽

Generalized Anxiety ◽

Open Label ◽

Open Label Study ◽

Label Study

Download Full-text

Ramelteon for Insomnia Symptoms in a Community Sample of Adults with Generalized Anxiety Disorder: An Open Label Study

Journal of Clinical Sleep Medicine ◽

10.5664/jcsm.27389 ◽

2009 ◽

Vol 05 (01) ◽

pp. 28-33 ◽

Cited By ~ 26

Author(s):

Paul K. Gross ◽

Rosemary Nourse ◽

Thomas E. Wasser

Keyword(s):

Anxiety Disorder ◽

Generalized Anxiety Disorder ◽

Community Sample ◽

Generalized Anxiety ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Insomnia Symptoms

Download Full-text

Mirtazapine treatment of Generalized Anxiety Disorder: a fixed dose, open label study

Journal of Psychopharmacology ◽

10.1177/0269881105056527 ◽

2005 ◽

Vol 19 (5) ◽

pp. 483-487 ◽

Cited By ~ 36

Author(s):

Francesco Gambi ◽

Domenico De Berardis ◽

Daniela Campanella ◽

Alessandro Carano ◽

Gianna Sepede ◽

...

Keyword(s):

Anxiety Disorder ◽

Generalized Anxiety Disorder ◽

Fixed Dose ◽

Generalized Anxiety ◽

Open Label ◽

Open Label Study ◽

Label Study

Download Full-text

Quetiapine XR adjunctive treatment in partially responsive generalized anxiety disorder (GAD): An open label study

Journal of Affective Disorders ◽

10.1016/j.jad.2010.02.069 ◽

2010 ◽

Vol 122 ◽

pp. S58

Author(s):

A. Gabriel

Keyword(s):

Anxiety Disorder ◽

Generalized Anxiety Disorder ◽

Adjunctive Treatment ◽

Generalized Anxiety ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Quetiapine Xr

Download Full-text

An Open-Label Study to Evaluate Switching from an SSRI or SNRI to Tiagabine to Alleviate Antidepressant-Induced Sexual Dysfunction in Generalized Anxiety Disorder

Annals of Clinical Psychiatry ◽

10.1080/10401230601163535 ◽

2007 ◽

Vol 19 (1) ◽

pp. 25-30 ◽

Cited By ~ 7

Author(s):

Thomas L. Schwartz ◽

George S. Nasra ◽

Adam K. Ashton ◽

David Kang ◽

Hari Kumaresan ◽

...

Keyword(s):

Anxiety Disorder ◽

Sexual Dysfunction ◽

Generalized Anxiety Disorder ◽

Generalized Anxiety ◽

Open Label ◽

Open Label Study ◽

Label Study

Download Full-text

Pregabalin augmentation of antidepressants in older patients with comorbid depression and generalized anxiety disorder-an open-label study

International Journal of Geriatric Psychiatry ◽

10.1002/gps.3800 ◽

2012 ◽

Vol 28 (1) ◽

pp. 100-105 ◽

Cited By ~ 11

Author(s):

Dimitrios Karaiskos ◽

Dimitra Pappa ◽

Elias Tzavellas ◽

Kostas Siarkos ◽

Everina Katirtzoglou ◽

...

Keyword(s):

Anxiety Disorder ◽

Generalized Anxiety Disorder ◽

Older Patients ◽

Generalized Anxiety ◽

Comorbid Depression ◽

Open Label ◽

Open Label Study ◽

Label Study

Download Full-text

Short-term tolerability of a nonazapirone selective serotonin 1A agonist in adults with generalized anxiety disorder: A 28-day, open-label study

Clinical Therapeutics ◽

10.1016/j.clinthera.2008.09.006 ◽

2008 ◽

Vol 30 (9) ◽

pp. 1658-1666 ◽

Cited By ~ 2

Author(s):

Sanjay J. Mathew ◽

Amir Garakani ◽

John F. Reinhard, Jr ◽

Scott Oshana ◽

Stephen Donahue

Keyword(s):

Anxiety Disorder ◽

Generalized Anxiety Disorder ◽

Selective Serotonin ◽

Generalized Anxiety ◽

Short Term ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Term Tolerability

Download Full-text

P.096 Efficacy of agomelatine on anxiety symptoms and functional impairment in adult patients with generalized anxiety disorder

European Neuropsychopharmacology ◽

10.1016/j.euroneuro.2020.09.082 ◽

2020 ◽

Vol 40 ◽

pp. S60

Author(s):

J.P. Khoo ◽

F. Picarel-Blanchot ◽

V. Olivier ◽

S. Dan

Keyword(s):

Anxiety Disorder ◽

Generalized Anxiety Disorder ◽

Functional Impairment ◽

Anxiety Symptoms ◽

Adult Patients ◽

Generalized Anxiety

Download Full-text

Long-term efficacy and safety of agomelatine in non-depressed out-patients with generalized anxiety disorder. A 26-week randomised double-blind placebo-controlled parallel group study following an open-label period of 16 weeks with agomelatine (25 mg/day with the possibility for blinded dose-adjustment to 50 mg/day)

http://isrctn.org/> ◽

10.1186/isrctn38094599 ◽

2012 ◽

Author(s):

Istvan Bitter

Keyword(s):

Anxiety Disorder ◽

Generalized Anxiety Disorder ◽

Dose Adjustment ◽

Generalized Anxiety ◽

Efficacy And Safety ◽

Open Label ◽

Double Blind ◽

Double Blind Placebo ◽

Parallel Group

Download Full-text

A phase 1b multicenter, open-label study of investigational TAK-228 (MLN0128) plus TAK-117 (MLN1117) in adult patients with advanced nonhematologic malignancies

European Journal of Cancer ◽

10.1016/s0959-8049(16)32625-9 ◽

2016 ◽

Vol 69 ◽

pp. S11-S12 ◽

Cited By ~ 3

Author(s):

D. Juric ◽

J. Lopez ◽

D. Rasco ◽

T. Macarulla Mercadé ◽

Q. Xu ◽

...

Keyword(s):

Adult Patients ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Phase 1B

Download Full-text

Quetiapine. A collection of useful information for the clinician

Medycyna Faktów ◽

10.24292/01.mf.0221.7 ◽

2021 ◽

Vol 14 (2) ◽

pp. 182-185

Author(s):

Marcin Siwek

Keyword(s):

Bipolar Disorder ◽

Anxiety Disorder ◽

Generalized Anxiety Disorder ◽

Antipsychotic Drug ◽

Medical Practice ◽

Anxiety Symptoms ◽

Use Cases ◽

Generalized Anxiety ◽

Recurrent Depression ◽

Proven Efficacy

Quetiapine is an antipsychotic drug with proven efficacy in the treatment of schizophrenia and bipolar disorder as well as recurrent depression and generalized anxiety disorder. There is also evidence of the efficacy of quetiapine in other disorders dominated by affective and/or anxiety symptoms, for which treatment is not registered in Poland. The paper presents information useful in medical practice and presents descriptions of use cases.

Download Full-text